Advances in the Treatment of COVID-19 Phase 9


Time :

2022-12-16

Anticoagulants should be used in COVID-19 patients without contraindications. At present, some scholars believe that novel coronavirus can promote thrombosis. On March 26, the International Society for Thrombosis and Hemostasis recommended that all hospitalized COVID-19 patients, even if they are not critically ill patients who need to be admitted to the intensive care unit, should apply prophylactic doses of low molecular weight heparin as long as there are no contraindications.

Anticoagulants should be used in COVID-19 patients without contraindications. At present, some scholars believe that novel coronavirus can promote thrombosis. On March 26, the International Society for Thrombosis and Hemostasis recommended that all hospitalized COVID-19 patients, even if they are not critically ill patients who need to be admitted to the intensive care unit, should apply prophylactic doses of low molecular weight heparin as long as there are no contraindications.
Recently, a study published by researchers at Wuhan Tongji Hospital showed that in severe COVID-19 patients with coagulation disorders (meeting the criteria for coagulation disorders caused by sepsis or significantly elevated D-dimer levels), the application of low molecular weight heparin Anticoagulant drugs such as heparin can reduce mortality by 28 days
Tongji Hospital Study - A total of 449 patients with severe COVID-19 were enrolled, of which 99 were treated with heparin for at least 7 days. Among patients with and without heparin, there was no significant difference in 28-day mortality. However, among patients whose sepsis-induced coagulation disorder score was 24 (40.0% vs 64.2%) and whose D-dimer exceeded the upper limit of normal by 6 times (32.8% vs 52.4%), the 28-day mortality of patients treated with heparin was significantly reduced.
A study by researchers at the Icahn School of Medicine at Mount Sinai in New York, USA, published online May 6 in JACC Priority, further found that the use of anticoagulants improved survival for all COVID-19 hospitalized patients.
After observing nearly 3,000 COVID-19 hospitalized patients in the United States, researchers found that after the use of anticoagulants, the median survival time of patients increased from 14 days to 21 days (mortality rate decreased from 22.8% to 22.5%). The effect of anticoagulants was particularly pronounced in critically ill patients who required mechanical ventilation with an upper respirator: The in-hospital mortality rate of these patients decreased from 62.7% to 29.1%, and the median survival time increased from 9 days to 21 days.
It can be seen that heparin drugs are indispensable drugs for the treatment of severe COVID-19 patients.